cancer - International Biopharmaceutical Industry

news

Biopharma Takes on Deadly Brain Cancer After Decades of Failure

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics and others are targeting the often-fatal...

2 December 2024 news biopharma | biopharmaceutical

Continue Reading →

news

Adcendo Raises $135m for Cancer ADCs, and Other Financings

Adcendo has tapped into the strong investor appetite for companies developing antibody-drug conjugates for cancer with an oversubscribed second round that raised $13...

2 December 2024 news Adcendo | Antibody

Continue Reading →

news

FDA Oncology Advisory Committee to Weigh Exelixis’ Cabometyx in Neuroendocrine Tumours

The advisory committee will meet to discuss Cabometyx's phase 3 CABINET study in March 2025. Before Exelexis’ Cabometyx can pass muster with the FDA in its hopefu...

2 December 2024 news biopharma | cancer

Continue Reading →

news

Adaptimmune Gears Up for Potential Approval of First-in-Class Engineered T Cell Therapy

After more than a decade devoid of therapeutic advancements, a first-in-class T cell receptor therapy could be on the immediate horizon for synovial sarcoma patients...

29 July 2024 news cancer | FDA

Continue Reading →

Volume 5 Issue 3

ADCs – From Lab to Clinical Development

Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. Compared to traditional small-molecule approaches, ADCs offer...

12 October 2022 Volume 5 Issue 3 agents | Antibody

Continue Reading →

news

Regeneron buys control of cancer drug Libtayo from Sanofi

Dive Brief: Regeneron will pay partner Sanofi $900 million to gain global rights to the companies’ cancer immunotherapy Libtayo, announcing Thursday a deal executi...

6 June 2022 news cancer | Drug

Continue Reading →

news

Merck study results signal blood cancer potential for new type of immunotherapy

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat Merck to a notable ...

30 May 2022 news blood | Bristol

Continue Reading →

news

Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive gene called KRAS. Upd...

30 May 2022 news Amgen | cancer

Continue Reading →

news

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

Dive Brief: A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form of lung ca...

13 May 2022 news cancer | Drug

Continue Reading →

news

Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

Dive Brief: Taiho Pharmaceutical is buying back rights to an experimental cancer drug aimed at a genetic driver of lung tumors after licensing it to Cullinan Oncol...

13 May 2022 news cancer | Cullinan

Continue Reading →

Current Edition

Upcoming Events

Advertisement

Biopharma Takes on Deadly Brain Cancer After Decades of Failure

Adcendo Raises $135m for Cancer ADCs, and Other Financings

FDA Oncology Advisory Committee to Weigh Exelixis’ Cabometyx in Neuroendocrine Tumours

Adaptimmune Gears Up for Potential Approval of First-in-Class Engineered T Cell Therapy

ADCs – From Lab to Clinical Development

Regeneron buys control of cancer drug Libtayo from Sanofi

Merck study results signal blood cancer potential for new type of immunotherapy

Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

International Biopharmaceutical Industry